Twelve clarithromycin-resistant Helicobacter pylori isolates (100% of resistant isolates examined) from seven different patients each contained an A3G transition mutation within a conserved loop of 23S rRNA. A3G transition mutations at positions cognate with Escherichia coli 23S rRNA positions 2058 and 2059 were identified. Clarithromycin-susceptible H. pylori isolates from 14 different patients displayed no polymorphisms in a conserved loop within domain V of 23S rRNA. The study is the first to report mutations in H. pylori associated with resistance to an antimicrobial agent used in established peptic ulcer treatment regimens.
The National Institutes of Health Consensus Conference in 1994 recommended that all patients with peptic ulcer disease and documented Helicobacter pylori infection be treated with appropriate antibacterial therapy (19) . Multiple studies have demonstrated that cure of H. pylori infection results in cure of peptic ulcer disease (9, 12, 24) . Cure of H. pylori infection may reduce the risk of gastric adenocarcinoma and has been associated with regression of gastric mucosa-associated lymphoid tissue (MALT) lymphoma (1, 23, 28) . The highest cure rates have been obtained with multiple antimicrobial treatment regimens that include an imidazole (i.e., metronidazole) or clarithromycin and that usually last 7 to 14 days (for reviews, see references 13, 15, and 25) . Resistance to clarithromycin accounted for 71% of treatment failures (five of seven treatment failures) in one limited study (3) . In a separate study, Logan et al. (14) achieved a 78% cure rate with clarithromycin-omeprazole dual therapy. Ninety-three percent of H. pylori strains were susceptible to clarithromycin prior to treatment, but 20% of patients who were treatment failures yielded posttreatment isolates resistant to clarithromycin. Recent data from western Europe indicate that greater than 60% of treatment failures with clarithromycin-based protocols are associated with the presence of clarithromycin-resistant H. pylori isolates after therapy (4, 29) .
Previous biochemical data, in addition to mutational analyses of 23S rRNA genes from various organisms (for a review, see reference 27), motivated us to examine domain V of 23S rRNA genes of clarithromycin-resistant H. pylori isolates. Twenty-eight H. pylori isolates were cultured from gastric antral biopsy specimens obtained from 17 H. pylori isolates were passaged routinely on brain heart infusion agar containing 7% fresh horse blood and were incubated at 37ЊC with 12% CO 2 and 98% humidity. Agar dilution studies were performed on Mueller-Hinton agar plates (Difco Laboratories, Detroit, Mich.) supplemented with 5% horse blood (BBL Microbiology Systems, Cockeysville, Md.) by an agar dilution method as described by Hardy et al. (10) . Plates containing serial dilutions of the antibiotic were inoculated with approximately 10 6 CFU per spot by using a multipoint replicating device (Steer's replicator; Craft Machines, Chester, Pa.). Incubation was at 37ЊC for 3 days under microaerophilic conditions generated by CampyPak Plus (BBL Microbiology Systems) in GasPak jars.
Prior to harvesting of the cells, H. pylori isolates were examined microscopically following Gram staining to confirm the expected gram-negative, helical morphology. Isolates were verified as H. pylori by biochemical tests positive for catalase, oxidase, and urease activities. Genomic DNA was isolated from lysed H. pylori cells following phenol-chloroform extraction and ethanol precipitation as described previously (7). To examine the conserved domain V by DNA sequencing, primers 18 (5Ј-AGTCGGGACCTAAGGCGAG-3Ј; complementary to cognate Escherichia coli 23S rRNA positions 1342 to 1360) (16) and 21 (5Ј-TTCCCGCTTAGATGCTTTCAG-3Ј; complementary to positions 2765 to 2745) (16) amplified an approximately 1.4-kb amplicon in each isolate. PCR amplicons were purified by membrane filtration with Microcon-100 tubes according to the instructions of the manufacturer (Amicon, Beverly, Mass.). Approximately 400 ng of each purified amplicon was added as template DNA in cycle DNA sequencing reactions. Five picomoles of the internal 23S rRNA oligonucleotide primer 19 (5Ј-GTAGCGAAATTCCTTGTCGG-3Ј; complementary to cognate E. coli positions 1930 to 1949) (16) was end-labeled with ␥-33 P by T4 polynucleotide kinase and was used as the sequencing primer. The 23S rRNA amplicons were sequenced by dideoxy termination during linear amplification according to the instructions of the manufacturer (dou-ble-stranded DNA Cycle Sequencing System; GIBCO BRL, Gaithersburg, Md.). A 50-bp region (cognate with E. coli positions 2046 to 2095) within domain V of 23S rRNA was analyzed and was manually aligned between the different H. pylori isolates.
The susceptibilities of the H. pylori isolates to the macrolides clarithromycin or azithromycin were evaluated by agar dilution experiments. Of 28 H. pylori isolates from 17 patients, 16 susceptible isolates from 14 patients and 12 clarithromycin-resistant isolates from 7 patients were obtained ( Table 1 ). All clarithromycin-resistant isolates demonstrated cross-resistance to azithromycin (data not shown). MICs of clarithromycin for resistant isolates were variable (Table 1 ) and included MICs of 2 g/ml (intermediate resistance; n ϭ 1), 4 g/ml (n ϭ 2), 8 g/ml (n ϭ 1), 16 g/ml (n ϭ 4), 32 g/ml (n ϭ 3), and 128 g/ml (n ϭ 1). H. pylori isolates obtained from four patients with a posttreatment resistant isolate were susceptible to clarithromycin prior to treatment. Serial H. pylori isolates from the same patient that were susceptible and later resistant to clarithromycin yielded similar DNA fingerprints (data not shown), suggesting that individual mutant isolates arose within a single clone and were selected with antimicrobial treatment. Patient I yielded resistant isolates 1 and 2 months after monotherapy with clarithromycin. Interestingly, susceptible isolates were obtained 4 and 7 months after treatment. Wild-type H. pylori may thrive relative to mutant clones in the absence of therapeutic pressure in vivo. For example, E. coli clones containing a mutant 23S rRNA gene in a multicopy plasmid had extended doubling times in the absence of macrolides (26) .
Cycle DNA sequencing of the 23S rRNA gene amplicons revealed the presence of point mutations in domain V associated with clarithromycin resistance. Two different A3G transition mutations at positions cognate with E. coli 23S rRNA positions 2058 and 2059 were identified in all resistant isolates (Fig. 1) . Of the 12 mutations identified, 10 were A to G transitions at position 2059 (A2059G) (five patients) and 2 were A2058G (two patients). Three of seven patients with H. pylori strains containing mutations in 23S rRNA domain V either did not heal following treatment or had a recurrence of duodenal ulcer disease during the 6 to 7 months of follow-up evaluation ( Table 1 ). The predominant transition mutation, A2059G, created an additional BsaI site that was evident following BsaImediated restriction digestion of 23S rRNA gene amplification products (Fig. 2) . Isolates with the A2058G mutation did not create an additional BsaI recognition site and appeared to be the wild type by BsaI-mediated digestion (Fig. 2) . None of the 16 susceptible isolates contained polymorphisms in the conserved loop region depicted in Fig. 1 . One isolate, isolate Q2, demonstrated evidence of heterozygosity in the 23S rRNA gene (data not shown). Purification of a single colony of isolate Q2 and subsequent DNA sequencing yielded both A and G residues at position 2058. Since the population of bacteria in a single colony is clonal, presumably one copy of the 23S rRNA gene in isolate Q2 is that of the wild type and the other copy is that of the mutant.
Macrolides (22) such as erythromycin and clarithromycin inhibit nascent peptide chain elongation by interacting with the 50S ribosomal subunit and stimulating the release of peptidyltRNA from the A site (17) . Biochemical studies have demonstrated a direct interaction of clarithromycin and its chief metabolite, 14-hydroxyclarithromycin, with 50S ribosomal subunits isolated from H. pylori (8) . Footprinting experiments have demonstrated a direct physical interaction between erythromycin and the conserved region V of E. coli 23S rRNA (18) . Specifically, the 23S rRNA residues A2058 and A2059 were protected when intact 70S ribosomes were incubated directly with erythromycin. Mutations conferring macrolide resistance occurred at or adjacent to the site of methylation (cognate to E. coli 23S rRNA position 2058) of 23S rRNA in Bacillus stearothermophilus (20) , previously known to confer erythromycin (macrolide) resistance. The A2058G mutation has been associated with macrolide resistance in E. coli isolates containing the 23S rRNA gene in a multicopy plasmid (26) , Mycobacterium avium-M. intracellulare (16) , plant choroplasts (5, 11), and yeast mitochondria (21) . Importantly, the principal muta- on January 21, 2018 by guest http://aac.asm.org/ tion found in the present study, A2059G, has not been reported previously in bacteria, although it has been associated with lincomycin resistance in plant chloroplasts (5). The current study presents evidence of the dominance of the mutant 23S rRNA allele. In contrast to M. avium-M. intracellulare, which possesses a single copy of the rRNA operon, two copies of the rRNA operon apparently exist in the H. pylori genome (2) . One cannot exclude the possibility of variant 23S rRNA gene copy numbers in different H. pylori strains. Nevertheless, the heterozygosity of 23S rRNA or the presence of one mutant 23S rRNA gene and one wild-type 23S rRNA gene on the same H. pylori chromosome appears to confer a phenotype of clarithromycin resistance. A more complex heterozygous state in E. coli isolates with multiple wild-type 23S rRNA chromosomal genes and multicopy plasmids containing a mutant 23S rRNA gene was associated with macrolide resistance (6, 26) . A single point mutation within domain V of 23S rRNA may be sufficient for conferring macrolide resistance in organisms containing a single rRNA operon, such as Mycobacterium spp. (16), or two rRNA operons, such as H. pylori. Although the use of macrolides such as erythromycin and clarithromycin has been widespread, the incidence of resistance in North American H. pylori isolates remains relatively low. Nevertheless, widespread oral therapy with macrolides for presumptive respiratory or gastrointestinal tract infections may increase the prevalence of resistant H. pylori isolates.
